Search PubMed⌕ Search

Biomedical subjects

J R Searle

Publications and source records attributed to J R Searle.

23 records · Page 2Linked to original sources
PubMedDate not supplied

In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure.

In an in vitro cell growth assay, carboplatin potency against A-431 cells increased after a 1 hour PMF (pulsed magnetic field) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTeslarms; pulses rose for 120 microseconds and then abruptly fell to neutral, and were repeated at a rate of 100 or 250 pulses per second). This potentiating effect was not observed with cisplatin or daunomycin. When cytotoxicity against HT-29 cells was measured, PMF exposure potentiated both carboplatin and daunomycin, but again, not cisplatin. Both cell types exhibited increased growth when exposed only to PMF. Exposure to PMF consistently increased the cell growth of these cancer cell lines, while only some in vitro antineoplastic agents were potentiated by PMFs.

Carboplatin↗
PubMedDate not supplied

Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure.

Immune deficient mice growing xenografts of HT-29 or A-431 cell lines were treated with cisplatin, carboplatin or doxorubicin in combination with one hour of wholebody pulsed magnetic field (PMF) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTeslarms; pulses rose for 120 microseconds and then abruptly fell to neutral, and were repeated at a rate of 250 pulses per second). At 24 days, the mice in each experiment were found to have significantly (p < 0.05, ANOVA) different tumor sizes among groups. The smallest mean tumor volume was consistently found in the drug+PMF group. With A-431 tumors, the cisplatin+PMF group (T) was significantly smaller, 52% [1-(100T/C)], than the cisplatin alone group (C). In HT-29 tumors, those treated with carboplatin+PMF had the smallest tumor volume at just 34% of the carboplatin-alone group. In HT-29 tumors, the doxorubicin+PMF group was 35% of the doxorubicin alone group.

Animals↗